Terumo stock
4543.TJPXTerumo Corporation, HealthcareISIN JP3546800008
76Score 76 out of 100, Strong
Price and trend
85 / 100
Price history
+0.5% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 4.3% below its 52-week high. Largest decline in 20 years: 56% (January 2008 to February 2009).
Chart figures for advanced users
- SMA 50$14.88
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.99
- The lowest closing price of the last twelve months.
- Resistance$16.78
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Terumo Corporation belongs to the Medical (Devices) industry (Japan) and, with a market value of $23.7B, is number 11 of 90 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $7.11B (up 9.2% year on year) and earnings of $853.55M (up 16.2%).
- For fiscal 2027, analysts expect on average revenue of $7.88B (up 10.9%) and adjusted earnings per share of $0.64 (up 10.3%).
Show more
- MEQIRI Score 76 out of 100 (Strong): rank 48 of 714 in Healthcare, median 53.
- The P/E is 22.9 (Medical (Devices) median 25.6, own median of recent years 31.7).
- Our model puts fair value at $13.86, with the price 14% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 17 years.Capital allocation 68
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 84
- Earnings turn into cashFree cash flow 117% of earnings over the last 12 months.Fundamentals 84
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and technical analysis.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $10.66 and expensive above $19.81 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $9.80 (cash-flow model) and $17.92 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 6.6%. At 7.6% the fair value would be $12.96, at 5.6% it would be $15.18.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 14% on the twelve months before. Revenue has grown solidly since 2007, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 53%, operating 16%, net 12%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Feb 2027in 90 days
- Last reported
- 12 Nov 2026EPS reported −$0.07 (expected $0.01)below expectations
Analyst estimates
Earnings estimates have barely changed since 24 Oct 2026.
- Earnings per share
- $0.64+0.1%
- Revenue
- $7.88B0.0%
- Earnings per share
- $0.810.0%
- Revenue
- $8.31B−0.1%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Terumo
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- GE HealthCare TechnologiesGEHC $37.35B69
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- DexComDXCM $29.97B78
- Koninklijke PhilipsPHIA.AS $29.51B56
- Zimmer Biomet HoldingsZBH $20.34B68
- Sonova HoldingSOON.SW $20.24B74
- GlaukosGKOS $14.63B48
- Smith & NephewSNN $12.99B67
ETFs that hold Terumo
Held by 85 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Nikkei 225 UCITS ETF 2D EUR HedgedXDJE | 1.16% | 0.19% | €2.56B |
| Xtrackers MSCI Japan ESG UCITS ETF 1CXZMJ | 0.88% | 0.20% | €2.69B |
| Amundi MSCI Japan ESG Broad Transition UCITS ETF EUR AccJ1GR | 0.67% | 0.15% | €1.31B |
Show 5 more
| Xtrackers MSCI Japan Screened UCITS ETF 3C EUR HedgedXDNE | 0.48% | 0.25% | €453.13M |
| UBS Core MSCI Japan UCITS ETF JPY dis DistributionUIM5 | 0.45% | 0.12% | €7.07B |
| Amundi MSCI Pacific ESG Broad Transition UCITS ETF DistX014 | 0.41% | 0.45% | €175.23M |
| L&G Japan Equity UCITS ETFETLR | 0.40% | 0.10% | €948.24M |
| Amundi Prime Japan UCITS ETF DR (D)PR1J | 0.39% | 0.05% | €4.21B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ¥159.23)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.